GENERICS AND BIOSIMILARS INITIATIVE JOURNAL
Official Journal of the Generics and Biosimilars Initiative
Volume 1 / Year 2012 / Issue 3-4
Perspective
Health professionals in the risk communication process on counterfeit medicines
Author(s): Luc Besançon
Page: 135-7Abstract: Communication is a key component in the fight against counterfeit medicines affecting the lives of patients. Two types of risk communication should be distinguished: pro-active and reactive. Reactive communication can be facilitated by appropriate pro-active communication strategies, and healthcare professionals can be powerful allies in communication activities targeting patients. Submitted: 27 July 2012; Revised: […]
Terminology for biosimilars–a confusing minefield
Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath
Page: 132-4Author byline as per print journal: Robin Thorpe, PhD, FRCPath; Meenu Wadhwa, PhD Abstract: Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for approval. Unfortunately, inconsistency in nomenclature for biosimilars has caused confusion. This problem of terminology has been the subject of a recent publication. The confusion is […]
